Range of concentrations of the drugs combined with phenylacetate and phenylbutyrate in these experiments with the 8226 and MY5 human myeloma cell linesa
| Drug . | 8226 (μm) . | MY5 (μm) . | Concentrations in μm achievable in humans (reference) . |
|---|---|---|---|
| Doxorubicin | 0.01–0.12 | 0.01–0.16 | 0.01–7 (596061) |
| Etoposide | 0.05–1.8 | 0.05–0.35 | 10–92 (62) |
| Topotecan | 0.05–0.5 | 0.1–2 | 0.01–0.1 (63, 64) |
| Cytarabine | 0.2–4 | 0.05–1 | 10–150 (65) |
| Chlorambucil | 5–120 | 10–125 | 2–6.3 (66, 67) |
| Melphalan | 1–80 | 2–30 | 1–13 (68, 69) |
| Fludarabine | 5–180 | 3–40 | 0.63–0.76 (70) |
| Cisplatin | 0.5–12 | 1–20 | 8–30 (717273) |
| Carboplatin | 8–130 | 10–160 | 1.4–13.5 (74) |
| Phenylacetate | 2000–20,000 | 2000–20,000 | 1360–4600 (28, 42, 43) |
| Phenylbutyrate | 250–3000 | 250–3000 | 1120–2020 (23, 29, 75) |
| Drug . | 8226 (μm) . | MY5 (μm) . | Concentrations in μm achievable in humans (reference) . |
|---|---|---|---|
| Doxorubicin | 0.01–0.12 | 0.01–0.16 | 0.01–7 (596061) |
| Etoposide | 0.05–1.8 | 0.05–0.35 | 10–92 (62) |
| Topotecan | 0.05–0.5 | 0.1–2 | 0.01–0.1 (63, 64) |
| Cytarabine | 0.2–4 | 0.05–1 | 10–150 (65) |
| Chlorambucil | 5–120 | 10–125 | 2–6.3 (66, 67) |
| Melphalan | 1–80 | 2–30 | 1–13 (68, 69) |
| Fludarabine | 5–180 | 3–40 | 0.63–0.76 (70) |
| Cisplatin | 0.5–12 | 1–20 | 8–30 (717273) |
| Carboplatin | 8–130 | 10–160 | 1.4–13.5 (74) |
| Phenylacetate | 2000–20,000 | 2000–20,000 | 1360–4600 (28, 42, 43) |
| Phenylbutyrate | 250–3000 | 250–3000 | 1120–2020 (23, 29, 75) |
Also included are concentrations of these drugs achievable in humans.